Quest Diagnostics (NYSE: DGX) director acquires shares via dividend reinvestment plan
Rhea-AI Filing Summary
Quest Diagnostics Inc. director Wright Lassiter III reported a small acquisition of common stock. On 2026-07-22, he acquired 6 shares at $206.813 per share through a dividend reinvestment plan administered by his broker, increasing his direct holdings to 10,323 shares. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report it early on Form 4. The Rule 10b5-1 checkbox was not marked as a trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6 shares
Net Buy
1 txn
Insider
Lassiter Wright III
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Small Acquisition | Common Stock F1 | 6 | $206.813 | $1K |
Holdings After Transaction:
Common Stock — 10,323 shares (Direct)
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Shares acquired: 6 shares of Common Stock
Price per share: $206.8130 per share
Post-transaction holdings: 10,323 shares
3 metrics
Shares acquired
6 shares of Common Stock
Shares acquired on 2026-07-22 via dividend reinvestment plan
Price per share
$206.8130 per share
Acquisition price for 6 Quest Diagnostics shares
Post-transaction holdings
10,323 shares
Direct ownership after the reported acquisition
Key Terms
dividend reinvestment plan, Rule 16a-6, Form 5
3 terms
dividend reinvestment plan financial
"Reflects shares that were acquired pursuant to a dividend reinvestment plan administered"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
Rule 16a-6 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
Form 5 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Wright Lassiter III report for DGX on this Form 4?
Wright Lassiter III reported a small acquisition of 6 shares of Quest Diagnostics common stock. The acquisition occurred on 2026-07-22 through a dividend reinvestment plan, and it increased his direct holdings to 10,323 shares following the transaction.
Why is Rule 16a-6 mentioned in the Quest Diagnostics (DGX) Form 4 filing?
Rule 16a-6 is cited because the dividend reinvestment plan acquisition was eligible for deferred reporting on Form 5. The reporting person voluntarily chose to disclose this small transaction early on Form 4 instead of waiting to include it on a later Form 5.
Was Wright Lassiter III’s DGX transaction made under a Rule 10b5-1 trading plan?
The filing does not characterize the transaction as under a Rule 10b5-1 plan. Instead, the footnote attributes the acquisition to a broker-administered dividend reinvestment plan, and the transaction is described as eligible for deferred reporting under Rule 16a-6.